Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q3 2022 · 10-Q
Revenue$127.01M$127.01M+61.1% vs Q3 2021 Net Income$457.00K$457.00K−94.3% vs Q3 2021 EPS Diluted$0.01$0.01−95.5% vs Q3 2021 Gross Profit$58,839,000+27.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$42,769,000+147.9% Free Cash Flowderived$42,656,000+151.2% Margins · derivedGross margin46.3%−12.2 pt vs Q3 2021
Operating margin16.1%−1.8 pt vs Q3 2021
Net margin0.4%−9.8 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 3, 2022 · 34 d after period end